TABLE 3.
MSC-based delivery of chemotherapy agents for cancer therapy.
| Cancer | Agent | Main results |
| Glioblastoma | PTX | Inducing the elimination of human pancreatic carcinoma (CFPAC-1) and glioblastoma (U87-MG) cell line in combination therapy with MSC-TRAIL in vitro (Coccè et al., 2020) |
| Pancreatic cancer | PTX | Marked antitumor effects on human pancreatic cell line CFPAC-1by MSC-PTX secretome (Coccè et al., 2019) |
| Breast cancer | PTX | Suppressing the viability of breast cancer MDA-MB-231 cells in vitro and in xenografts (Kalimuthu et al., 2018a) |
| Pancreatic cancer | PTX | Sustained and continued releases of PTX resulted in improved cell’s eradication (Brini et al., 2016) |
| Breast cancer | PTX | Stimulation of potent cytotoxicity against MCF-7 cell line in vitro (Salehi et al., 2018) |
| Prostate cancer | GCB | Inducing anti-proliferative effects on human pCa cell line in vitro (Bonomi et al., 2015) |
| Squamous cell carcinoma | PTX DXR GCB | Inducing a dramatic suppression of SCC154 cell line proliferation in vitro (Coccè et al., 2017) |
| Mesothelioma | PTX | Inhibiting the mesothelioma NCI-H28 cell proliferation (Petrella et al., 2017) |
| Glioma | DXR | Inducing anti-tumor effects in U251 glioma tumor cells bearing murine with broader distribution and prolonged retention lifetime compared with free DOX (Li et al., 2011) |
| Thyroid cancer Breast cancer | DXR | The pronounced tumor cell elimination in vitro and successful migration to tumor sites in xenografts by MSC-PTX (Kalimuthu et al., 2018b) |
| Multiple myeloma | PTX | Suppressing the myeloma RPMI 8226 cell proliferation in 3D cell culture system (Bonomi et al., 2017) |
| Lung carcionoma | PTX | Remarkable anti-tumor effects in orthotopic Lewis lung carcinoma (LL/2-luc) tumors established in C57BL/6 mice (Layek et al., 2018) |
| Ovarian cancer | PTX | Inhibition of ovarian cancer cells viability in 2D models and in 3D heterospheroids (Borghese et al., 2020) |
| Leukemia Osteosarcoma Prostate cancer Neuroblastoma | PTX | Potent cytotoxicity against MOLT4 (leukemia), SK-ES-I (anaplastic osteosarcoma), DUl45 (prostatic carcinoma), and GILI-N and SH-SY5Y (neuroblastoma) cell line in vitro (Bonomi et al., 2013) |
| Osteosarcoma | DXR | Marked antitumor effect against osteosarcoma MG63 cell line but low cytotoxicity in myocardial H9C2 cell line by MSC-exosome-PTX (Wei H. et al., 2019) |
| Pulmonary metastatic melanomas | DXR | Pronounced antitumor effects in pulmonary B16F10 melanoma metastases in vivo (Zhao et al., 2017) |
GCB, gemcitabine; PTX, paclitaxel; DOX, doxorubicin; MSCs, mesenchymal stem/stromal cells.